BBAR vs SLM

BBAR exhibits weak financial health with a Piotroski F-Score of just 2/9, indicating significant deterioration in fundamental performance. Despite strong long-term price appreciation, the stock trades at a premium valuation (P/E 30.28 vs sector avg 21.03) while facing sharp declines in revenue (-17.70% YoY) and earnings (-75.5% YoY). Earnings quality is poor, with 3 of the last 4 quarters missing estimates by an average of -45.13%, and key metrics like ROE (7.19%) and ROA (1.11%) remain below industry benchmarks. The lack of Altman Z-Score data raises transparency concerns, but the deterministic scorecard and deteriorating trends support a bearish outlook.

SLM presents a stark contradiction between explosive growth and deteriorating financial health, highlighted by a weak Piotroski F-Score of 2/9. While the stock is fundamentally undervalued with a P/E of 6.54 and trades below its Graham Number of $29.32, the low health score and bearish technical trend (0/100) suggest a potential value trap. Exceptional YoY earnings growth of 126.20% is offset by a high Debt/Equity ratio of 2.40 and a poor recent track record of earnings surprises. The discrepancy between the current price and the growth-based intrinsic value ($102.07) reflects significant market skepticism regarding the sustainability of its current trajectory.